Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 295

1.

Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout.

Dalbeth N, House ME, Horne A, Petrie KJ, McQueen FM, Taylor WJ.

BMC Musculoskelet Disord. 2012 Sep 16;13:174. doi: 10.1186/1471-2474-13-174.

2.

Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population.

Pui K, Gow PJ, Dalbeth N.

J Rheumatol. 2013 Jun;40(6):872-6. doi: 10.3899/jrheum.121301.

PMID:
23457380
3.

Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level.

Stamp LK, Barclay ML, O'Donnell JL, Zhang M, Drake J, Frampton C, Chapman PT.

Clin Pharmacol Ther. 2011 Sep;90(3):392-8. doi: 10.1038/clpt.2011.113.

PMID:
21796116
4.

The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age.

Jackson RL, Hunt B, MacDonald PA.

BMC Geriatr. 2012 Mar 21;12:11. doi: 10.1186/1471-2318-12-11.

5.

Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study.

Perez-Ruiz F, Atxotegi J, Hernando I, Calabozo M, Nolla JM.

Arthritis Rheum. 2006 Oct 15;55(5):786-90.

6.

Illness perceptions in patients with gout and the relationship with progression of musculoskeletal disability.

Dalbeth N, Petrie KJ, House M, Chong J, Leung W, Chegudi R, Horne A, Gamble G, McQueen FM, Taylor WJ.

Arthritis Care Res (Hoboken). 2011 Nov;63(11):1605-12. doi: 10.1002/acr.20570.

7.

Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.

Hatoum H, Khanna D, Lin SJ, Akhras KS, Shiozawa A, Khanna P.

Postgrad Med. 2014 Mar;126(2):65-75. doi: 10.3810/pgm.2014.03.2741.

PMID:
24685969
8.

Significance of the initiation time of urate-lowering therapy in gout patients: A retrospective research.

Feng X, Li Y, Gao W.

Joint Bone Spine. 2015 Dec;82(6):428-31. doi: 10.1016/j.jbspin.2015.02.021.

PMID:
26456042
9.

Adherence and persistence to urate-lowering therapies in the Irish setting.

McGowan B, Bennett K, Silke C, Whelan B.

Clin Rheumatol. 2016 Mar;35(3):715-21. doi: 10.1007/s10067-014-2823-8.

PMID:
25409858
10.

Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study.

Schumacher HR Jr, Evans RR, Saag KG, Clower J, Jennings W, Weinstein SP, Yancopoulos GD, Wang J, Terkeltaub R.

Arthritis Care Res (Hoboken). 2012 Oct;64(10):1462-70. doi: 10.1002/acr.21690.

11.
12.

Casebook consults: improving outcomes in gout (multimedia activity).

Doghramji PP, Mandell BF, Pope RS.

Am J Med. 2012 Aug;125(8):S1. doi: 10.1016/j.amjmed.2012.06.002.

PMID:
22840678
13.

Clinically insignificant effect of supplemental vitamin C on serum urate in patients with gout: a pilot randomized controlled trial.

Stamp LK, O'Donnell JL, Frampton C, Drake JM, Zhang M, Chapman PT.

Arthritis Rheum. 2013 Jun;65(6):1636-42. doi: 10.1002/art.37925.

14.

Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.

Wortmann RL, Macdonald PA, Hunt B, Jackson RL.

Clin Ther. 2010 Dec;32(14):2386-97. doi: 10.1016/j.clinthera.2011.01.008.

PMID:
21353107
15.

Patient and clinical characteristics associated with gout flares in an integrated healthcare system.

Rashid N, Levy GD, Wu YL, Zheng C, Koblick R, Cheetham TC.

Rheumatol Int. 2015 Nov;35(11):1799-807. doi: 10.1007/s00296-015-3284-3.

16.

As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout.

Tausche AK, Christoph M, Forkmann M, Richter U, Kopprasch S, Bielitz C, Aringer M, Wunderlich C.

Rheumatol Int. 2014 Jan;34(1):101-9. doi: 10.1007/s00296-013-2857-2.

PMID:
24026528
17.

Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.

Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C.

J Rheumatol. 2009 Jun;36(6):1273-82. doi: 10.3899/jrheum.080814.

PMID:
19286847
18.

Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis.

Halpern R, Mody RR, Fuldeore MJ, Patel PA, Mikuls TR.

Curr Med Res Opin. 2009 Jul;25(7):1711-9. doi: 10.1185/03007990903017966.

PMID:
19485724
19.

Serum urate levels and gout flares: analysis from managed care data.

Sarawate CA, Patel PA, Schumacher HR, Yang W, Brewer KK, Bakst AW.

J Clin Rheumatol. 2006 Apr;12(2):61-5.

PMID:
16601538
20.

Comprehensive dietary education in treated gout patients does not further improve serum urate.

Holland R, McGill NW.

Intern Med J. 2015 Feb;45(2):189-94. doi: 10.1111/imj.12661.

PMID:
25495503
Items per page

Supplemental Content

Support Center